pharma big data, david cocker

23

Upload: david-cocker

Post on 20-Jan-2017

107 views

Category:

Health & Medicine


1 download

TRANSCRIPT

Page 1: Pharma big data, david cocker
Page 2: Pharma big data, david cocker

My Structure

• Quick heads-up on the oncology space• Evolving complexity, big science and big data

• What has changed in available data?

• Challenges for pharma (old versus new)• Enlightenment versus disentanglement• Merging new technologies with old business models• Voilà: what is possible!

Page 3: Pharma big data, david cocker

Source: ASCO 2015

Page 4: Pharma big data, david cocker
Page 5: Pharma big data, david cocker
Page 6: Pharma big data, david cocker
Page 7: Pharma big data, david cocker

My three Vs

“Explosion of complexity”

The complexity of cancer treatment decisions today cannot be left in the hands of a physician only.

Page 8: Pharma big data, david cocker

What does big data look like?

Page 9: Pharma big data, david cocker

The era of disentanglement is upon us

Page 10: Pharma big data, david cocker

Leveraging technologies for a more complete view

New data

Technologies· Ontologies· Smart algorithms· Robotics

Private data· CTMS· Impact

Tools & applications

Connected Information

· Modeling (Monte Carlo sim)· Communication platforms· Custom visualizations

· Aggregation· Data ranking· Summary statics

Application is any activity independent of the data source. It can be part of a connected process platform or independent

Page 11: Pharma big data, david cocker

One challenge

Adoption

Page 12: Pharma big data, david cocker

1.59 MILLION DEATHS 2012LUNG CANCER

NEED MORE PATIENTS & INVESTIGATORS

Page 13: Pharma big data, david cocker

"

Page 14: Pharma big data, david cocker

Investigator interest, capability, and willingness

HighLow

Page 15: Pharma big data, david cocker
Page 16: Pharma big data, david cocker

Lung cancer, impact per phase on top enrollment sites

Contribution top 10 organizations

Phase 1Phase 2

Page 17: Pharma big data, david cocker

USA

Greece

S Korea

France

Russia

India

Australia

Canada

UK

Italy China

Spain

Poland

Bulgaria

Taiwan

Japan

Free Capacity Ratio

Almost full

Still opportunities

Bloc

ked

Germany

# site

Page 18: Pharma big data, david cocker

BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice

Global feasibilityRecruitment assumptions

Operational choices· Country allocation· Site selection· Investigator selection

Supplementing investigator signature with claims and ethnicity data

Page 19: Pharma big data, david cocker

BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice

Global feasibilityRecruitment assumptions

Operational choices· Country allocation· Site selection· Investigator selection

Mapping site activity by competing drugs

Page 20: Pharma big data, david cocker

BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice

Global feasibilityRecruitment assumptions

Operational choices· Country allocation· Site selection· Investigator selection

Scenario modeling

Modeling (Monte Carlo simulation)

Page 21: Pharma big data, david cocker

BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice

Global feasibilityRecruitment assumptions

Operational choices· Country allocation· Site selection· Investigator selection

Epidemiology

Site Properties Mapping out the big picture (Reporting)

Page 22: Pharma big data, david cocker

BUSINESS QUESTIONSDesign & specifications· Current disease management· Standards of care seeking advice

Global feasibilityRecruitment assumptions

Operational choices· Country allocation· Site selection· Investigator selection

Epidemiology

Aggregated view of a high-profile clinical investigator

Page 23: Pharma big data, david cocker

Would you let your kid fly a A380 without any training?